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Cathepsin D is an  estrogen  (17P-estradio1,  E,)-induci- 
ble lysosomal protease. A putative estrogen receptor 
(ER)-Spl-like  sequence (GGGCGG(n),&CGGG) has  been 
identified  in  the,non-coding  strand of the  cathepsin D 
promoter  (-199  to  -165),  and  electromobility  shift  assays 
of  nuclear  extracts  from MCF-7 and  HeLa cells confirm 
that both the ER and Spl protein  bind  to  ”P-labeled 
EWSpl  oligo.  For  example,  nuclear  extracts  from MCF-7 
cells bind  to  the  32P-labeled  EWSpl  oligo;  however, EW 
Spl binding  can  be  decreased by selective  competition 
with  excess  unlabeled  estrogen  responsive  element  and 
Spl oligos,  immunodepletion  with ER or Spl antibodies, 
and  by treating  cells  with IC1 164,384,  an  antiestrogen 
which  inhibits  formation  of ER homodimer.  Moreover, 
E,-induced  chloramphenicol  acetyltransferase (CAT) ac- 
tivity  in MCF-7 cells  cotransfected  with  a human estro- 
gen  receptor  expression  plasmid  and  a  plasmid  contain- 
ing an EWSpl  sequence  cloned  upstream  to a thymidine 
kinase promoter and a CAT reporter. In cotreatment 
studies, IC1 164,384  inhibited  E,-induced CAT activity.  In 
contrast, E, did  not  induce CAT activity in MCF-7 cells 
transfected  with  plasmids  containing  mutations  in  the 
ER or Spl segments  of  the  EWSpl  oligo,  thus  confirming 
that  both  cognate  binding sites are  required  for  estro- 
gen  responsiveness. 
MCF-7 human  breast cancer cells express  the estrogen  re- 
ceptor (ER)’ and  represent a prototypical estrogen-responsive 
cell line which has been  extensively  utilized for mechanistic 
studies on estrogen- and antiestrogen-induced  responses (1-3). 
Cathepsin D is an  aspartyl protease, and  the role of estrogens 
on the intracellular regulation of procathepsin D, a 52-kDa 
protein, and CATH-D (a 34-kDa  protein) have been extensively 
investigated (1-12). 17P-Estradiol (E,) significantly increases 
CATH-D gene transcription and intracellular protein forma- 
tion, and  within 24 h after hormone treatment,  the extracellu- 
lar levels of the 52- and 34-kDa proteins are also  significantly 
increased. This induction  response is  not  inhibited by the non- 
steroidal  partial  antiestrogen, tamoxifen (7, 131, whereas IC1 
164,384, a steroidal “pure”  antiestrogen,  inhibits CATH-D gene 
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transcription  (7, 13-15).  CATH-D also  exhibits mitogenic activ- 
ity, and Briozzo and co-workers (16) reported  that  this protease 
degraded the extracellular  matrix of endothelial bovine corneal 
cells (17). This observation led to  the suggestion that CATH-D 
secreted from breast cancer cells facilitates tumor invasiveness 
and metastasis (17, 18). Subsequent studies reported that 
there  was no correlation  between CATH-D secretion and  tumor 
invasiveness in  the Boyden chamber assay of invasion (19). 
Although the precise role of this protein in  the development of 
breast cancer has not  been determined, CATH-D. has been used 
clinically as a negative prognostic indicator for disease-free 
survival  in women with  breast cancer (20-24). 
E, induces the expression of the CATH-D gene in ER-respon- 
sive breast cancer cells by interacting  with  the  transcriptional 
machinery at the promoter level. In the absence of E,, the 
CATH-D gene  transcription is initiated at multiple transcrip- 
tion start sites I-V, however, E, exclusively initiates  transcrip- 
tion at the TATA-dependent transcription start site I on the 
CATH-D promoter (12). The promoter region of cathepsin D 
does not contain a classical palindromic estrogen-responsive 
element  (ERE) (25) but  contains  several GC-rich boxes which 
can bind to  the  transcription factor Spl(l2,26).  Spl-dependent 
activation of transcription is TATA box-dependent (27), and 
recent  studies  have identified important regulatory  sequences 
in  the promoter region of the E,-induced creatine  kinase B gene 
in which weak interactions between the ER and  an ERE DNA 
half-site are stabilized by an  adjacent  transcription factor, such 
as Spl(28).  The mechanism of estrogen  activation of the c-myc 
oncogene also involves similar interactions between the ER 
half-site and  the  Spl  element on the c-myc downstream  pro- 
moter (29). Interestingly, these  EWSpl  elements function in 
either  orientation as enhancer sequences, in vitro (28). 
We have identified a putative  EWSpl-like sequence in  the 
non-coding strand of the CATH-D promoter (i.e. 
GGGCGG(n),,ACGGG) (-199 to -1651, and  this  study  reports 
32P-labeled EWSpl binding of nuclear extracts from HeLa and 
MCF-7 cells using electromobility shift  assays (EMSAs). These 
assays  demonstrate ER and S p l  bind to  this oligo, and, utiliz- 
ing an EWSpl-thymidine kinase-CAT plasmid in transient 
transfection assays, E, induces chloramphenicol acetyltrans- 
ferase (CAT) activity in MCF-7 cells. The  results  indicate  that 
the EWSp1 sites are functional enhancer elements and are 
responsible for E,-induced TATA-dependent transcription of 
the CATH-D gene  in vivo. 
MATERIALS AND METHODS 
Chemicals,  Cells,  Antibodies, and Oligonucleotides-IC1  164,384  was 
kindly provided by Dr. A. Wakeling; the MCF-7 cells and HeLa cells 
were obtained  from  ATCC.  The  ERE  and  xenobiotic  responsive  element 
(XRE)  oligo  for the EMSAs  have  previously  been  described  (30,311.  The 
EWSpl,  ERISpl and EWSpl  oligos  (see  below)  were  synthesized by and 
purchased from the DNA Technologies  Laboratory,  Texas A&M Univer- 
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sity. The complementary strands were annealed and  the 5”overhangs 
were used for cloning into the thymidine kinase-CAT vector (25). MCF-7 
and HeLa cells were cultured, and nuclear  extracts were isolated as  
described elsewhere (32). The Sp l  oligo was  purchased from Promega 
Biological Research Products; the  human estrogen receptor (hER) was 
kindly provided by  Dr. Ming Tsai (Baylor College of Medicine). Rat ER 
antisera (ER Ab) and rat  ER peptide (ER blocking peptide) was kindly 
provided by Dr. Koji Yoshinaga (National Hormone and  Pituitary Pro- 
gram, NIH). Spl  monoclonal antibody (Spl Ab) was purchased from 
Santa Cruz Biotech (Santa Cruz, CA). 
strand), 5‘  GATCCTGGGCGGG  GCAACCTCGGGCA  CGCACAGCGC- 
The oligonucleotides were as follows. EWSpl oligo (antisense 
CCGGGCGGGGGGCGGGGA 3’; E W W  oligo (antisense  strand), 5’ 
CAGGGGGCGGGGA  3‘; EJUSpl oligo (antisense strand), 5’ GATCCT- 
GCGGGGA 3’. ER, Spl,  and  mutated bases are noted in bold type. 
EMSA-The oligonucleotides were annealed and labeled a t  the 5’ 
end using T4-polynucleotide kinase and [y-32PlATP (33). DNA binding 
was  measured  using EMSAs. Five to 10 pg of nuclear  extracts from 
MCF-7 or HeLa cells treated with 10 n~ E, for 24 h and different 
chemicals for the times as  indicated were incubated with 1 pg of  poly 
d(1-C) for 15 min a t  20 “C to bind nonspecific DNA-binding proteins. 
Following addition of 32P-labeled DNA (final concentration, 1 nM), the 
mixture was incubated for another 15 min a t  20 “C. Excess unlabeled 
DNA  (50-200-fold) was added 5 min before adding 32P-labeled DNA to 
compete for specific DNA-protein binding. Reaction mixtures were 
loaded onto a 7% non-denaturing polyacrylamide gel (acrylamide: 
bisacrylamide, 30:0.8) and  run a t  110 V in TBE buffer (0.09 M Tris, 0.09 
M borate and 2 mM EDTA, pH 8.3). Gels were dried and protein-DNA 
binding was visualized by autoradiography and quantitated with a 
Betagen Betascope 603 blot analyzer. 
Immunodepletion and  Super  Shift Assays-MCF-7 cells were main- 
tained in Dulbecco’s modified  Eagle’s-F-12 medium as  described earlier. 
The cells were treated with the appropriate chemicals and nuclear 
extracts were obtained. For immunodepletion studies, 5 pg of nuclear 
extract were incubated with 20 ng of Spl  Ab, 40 ng of ERAb, 100 ng of 
CATH-D Ab, and 40 ng of ER Ab (incubated for 18 h  with blocking 
peptide) for 2 h. These extracts were then subjected to EMSAs as de- 
scribed earlier. The gels were dried and subjected to autoradiography, 
and  the intensity of the specific bands was quantitated using  a Betagen 
Betascope 603 blot analyzer. For the  super  shift  studies  the sp cific and 
the nonspecific Ab were incubated for 20 min after incubation with 
radiolabeled probe. Aliquots of 20, 40, 40, 100, and 100 ng of  Ab were 
used for the  Spl, ER, ER + peptide, rabbit IgG, and mouse IgG, respec- 
tively. The extracts were subjected to EMSAs, and  the gels were dried 
and visualized using autoradiography. 
Cloning and CAT  Assays-The oligonucleotides were cloned into the 
thymidine kinase-CAT vector a t  the BamHI and Hind111 sites as  pre- 
viously described (25). Ligation products were transformed  into DH5a 
bacterial cells, and clones obtained were verified by restriction map- 
ping. Cultured MCF-7 cells (32) were cotransfected with a Polybrene 
(200 pg/ml) solution containing  10  pg of appropriate plasmid DNA and 
the hER plasmid. ARer 6 h,  the cells were shocked with 25% glycerol in 
Hank’s solution and washed twice with the  same solution and grown in 
Dulbecco’s  modified  Eagle’slF-12 medium (without phenol red)  and 5% 
stripped  fetal bovine serum. Cells were dosed 12  h after shocking with 
appropriate chemicals dissolved in Me,SO; control cells were treated 
with Me,SO alone (<0.1%). Two days later  the cells were removed by 
manual scraping, cell extracts were obtained, and 100 pg of protein 
extract were used to determine CAT activity as described elsewhere (33, 
34). The percent protein conversion into acetylated chloramphenicol 
was quantitated using the  countdmin obtained from the Betascope 603 
blot analyzer. The TLC plates were subjected to autoradiography  using 
a Kodak X-Omat film for a t  least 12 h. 
GATCCTGGGCGGG  CAACCTCGGGCA  CGCACAGCGCCCGGA- 
GGGCGGA ACAACCTCGGGCA CGCACAGCGCCCGGGCGGGGG- 
RESULTS 
Identification of ERISpl Elements on the Cathepsin D 
Promoter-The estrogen-responsive region of the CATH-D pro- 
moter is a 240-base pair fragment located at  -123 to -364  of the 
initiation codon (12). Examination of the non-coding strand 
revealed the following putative EWSpl  sites within this region: 
3’ -199 . . . GGGCGG (nIz3 ACGGG . . . -165  5’. An oligonucle- 
otide (49-mer), which included the ElUSpl site and adjacent 
elements, was  prepared  (ElUSpl oligo) and used in  the follow- 
ing  analysis of the role of ElUSpl in regulation of  E,-induced 
EWSpl- 
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FIG. 1. Binding of nuclear  extracts from MCF-7 cells to EWSpl 
oligo. The cells were treated with Me,SO (lane 1 )  or 10 n~ E, (lanes 
2-11); the nuclear  extracts were isolated and analyzed by electromobil- 
ity  shift assays  as described under “Materials and Methods.” The  re- 
tarded  EWSpl bands  (see arrow) were visualized by autoradiography 
and quantitated using a Betagen 604 Betascope blot analyzer. The 
intensity values in lanes 2-11 relative to the control band (lane I ,  100 
2 20%) were 150 2 11,40 2 8.42 f 7,38 2 5,42 2 6,30 2 3,lO * 2,143 
f 14,150 f 15, and 90 * 12% (lanes 2-11, respectively; means 2 S.D. for 
three determinations. The intensities in lanes 3-8 were all significantly 
lower (p < 0.05) than observed in the E,-treated cells (lam 2). 
CATH-D gene expression. 
EMSA Using Nuclear Extracts from MCF-7 Human Breast 
Cancer Cells-Fig. 1 illustrates  the characteristic EMSA pat- 
tern using nuclear extracts from  MCF-7  cells and 32P-labeled 
EWSpl oligo. The results show that nuclear extracts from  con- 
trol (Me,SO-treated) cells bound to the ElUSpl oligo (lane 1 ); 
binding was increased with extracts from E,-treated cells and 
decreased after preincubation with 50-, loo-,  and 200-fold ex- 
cess of unlabeled ERE (lanes 3-55) or unlabeled Spl (lanes 6-81 
oligos. In contrast, competition with a 50-, loo-, and 200-fold 
excess of a nonspecific XRE  oligo (31, 32)  (lanes 8-11) did not 
affect binding to the 32P-labeled EWSpl oligo. An additional 
estrogen-inducible band with higher mobility was also ob- 
served but not further investigated. The results  in Fig. 2 dem- 
onstrate  that incubation of nuclear extracts  with the EWSpl 
(wt) oligo results in formation of a retarded ER.Spl complex 
(lane 3) which is competitively displaced by  100-fold unlabeled 
oligo (lane 2). In contrast,  these  extracts do not form a retarded 
band with oligos mutated in the ERE half-site (lane 1) or the 
Spl  binding site (lane 4) .  
Effect of ER and  Spl Specific Antibodies on ERISpl Binding 
in EMSAs-Fig. 3 shows that when antibodies specifically 
raised against ER (lane 5) or Spl (lane 2) proteins are incu- 
bated with MCF-7  cell nuclear extracts for 20 min  following 
incubation with radiolabeled ElUSpl oligo, a band of decreased 
mobility is formed due  to super shifting of the EWSpl band by 
the specific antibodies. Incubation with nonspecific IgG does 
not affect EReSpl complex formation (Fig. 3, lanes 3 and 4) ;  
preincubation of the ER antibody with a peptide which blocks 
antibody function removes the specific antibody band (Fig.  3, 
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FIG. 2. EMSAs performed with the w S p 1  and ERE/- mu- 
tant oligos. Nuclear extracts from MCF-7 cells were otained as de- 
scribed under  “Materials  and Methods” and subjected to EMSAs using 
radiolabeled oligos mutated at  the ERE half-site (ERE) or at the Spl  
site ( S p l ) .  Lane 1 is an EMSA performed using the  mutated ERE site 
and i t  illustrates an   Spl  band with increased mobility when compared 
to lane 3 which is the wild-type (wt) EWSpl band  (see arrow). Lane 4 
is  an EMSA performed using an oligo mutated a t  the  Spl  site  and 
illustrates no significant EWSpl or Spl  bands. Lane 2 is an EMSA 
performed using radiolabeled wt EWSpl oligo  which is preincubated 
with  a 100-fold excess of unlabeled w t  EIUSpl oligo. 
lane 6). Preincubation of  MCF-7 cell nuclear  extracts  with the 
ER or Spl  antibodies for 2 h followed  by  EMSAs resulted in a 
significant decrease in  the  EWSpl binding (Fig. 4, lanes 3 and 
4). Preincubation with nonspecific IgG (lane 6 )  or peptide- 
blocked  ER antibody (lane 5 )  did not decrease EWSpl binding. 
These results indicate that immunodepletion of the nuclear 
extracts with ER or Spl  specific antibody can result  in de- 
creased formation of ER.Spl complexes in vitro. The above 
results support  our hypothesis that ER and Spl  proteins are 
directly involved in formation of these  enhancer complexes. 
EMSA of Nuclear Extracts from MCF-7 Cells Deated  with 
E,, ICI 164,384, and  E, + ICI 164,384”3,P-Labeled EWSp1 
binding of nuclear extracts from  MCF-7 cells cotreated with E, 
and 1 1.1~ IC1 164,384 for 8, 6, 4, and 2 h (Fig. 5, lanes 3-6, 
respectively) exhibited a time-dependent decrease in formation 
of the retarded band compared to Me,SO (control) or E,-treated 
cells (Fig. 5, lanes 1 and 2,  respectively), and  this is consistent 
with the reported effects of  IC1 164,384 on destabilization of the 
nuclear ER  homodimer (35). 
EMSA Pattern of Nuclear Extracts from HeLa Cells afier 
Dansfection with  an hER Expression Plasmid-Nuclear ex- 
tracts from HeLa cells transfected with an hER expression 
plasmid gave an EWSpl retarded band (Fig. 6, lane 1) which 
was increased in intensity after treatment with E, (lane 2) ;  in 
contrast, minimal EWSpl binding was observed in nuclear ex- 
tracts from untreated HeLa cells (lane 31, although a lower 
molecular weight retarded band (labeled S p l )  was observed. 
The effect of various unlabeled DNA sequences as competitors 
for 32P-labeled EWSp1 binding of nuclear  extracts from HeLa 
+ + +  + + +  + + + + + + 
1 2 3 4 5 6 7  
E R  and Spl antibodies on EWSpl binding. Cells were treated with 
FIG. 3. Effect of preincubation of MCF-7 nuclear extracts with 
Me,SO (lane I )  or 10  nM E, (lanes 2-7). The nuclear extracts were 
isolated and incubated with 40 ng of ER Ab (lane 3 )  or 20 ng of Spl Ab 
(lane 4 )  for 2 h. Lanes 5 and 6 were nuclear  extracts preincubated with 
nonspecific CATH-D IgG (100 ng) and ER Ab incubated overnight at  
4 “C with 10 pg/ml blocking peptide. The preincubated extracts were 
analyzed by electromobility shift  assays as  described under “Materials 
and Methods.” The retarded EWSpl  and Spl  bands (see arrows) were 
visualized by autoradiography and  quantitated using the Betagen 603 
Betascope blot analyzer. The intensity  values in lanes 2-7 relative to the 
control lane (lane I ,  100 f 20%) were 190 * 30,84 17, 110 f 15,200 
* 25, 195 14  and  85 * 10% (lanes 2-7, respectively; means * S.D. for 
three determinations). The intensities in lanes 3, 4 and 7 were all 
significantly lower ( p  e 0.05) than observed in the E,-treated cells (lane 
2). Specific preincubation with 100 x cold EWSpl oligo resulted in 
decreased EWSpl binding (lane 7). 
cells transfected  with  hER was also determined using EMSAs. 
Competition with a 100-fold excess of the following unlabeled 
oligos, EWSpl (lane 6), Spl  (lane 51, and ERE (lane 41, all 
decreased the intensity of the  EWSpl band. Preincubation with 
unlabeled ERE shifts the  EWSpl band to an  Spl-retarded com- 
plex (lanes 3 and 4). 
Northern Blot Analysis of Cathepsin D mRNA  in MCF-7 Cells 
in the Presence of 1 V M  ICZ 164,384-The time-dependent ef- 
fects of 1 VM IC1  164,384 on E,-induced  CATH-D  mRNA levels 
were determined in MCF-7 cells (Fig. 7). Compared to control 
(Me,SO) cells (lane 11, E, induces CATH-D mRNA levels. In 
cotreatment  studies, IC1  164,384 significantly inhibited E,-in- 
duced CATH-D  mRNA levels after exposure of the cells to the 
antiestrogen for 8 or 6 h (lanes 4 and 5 )  and  the inhibitory 
effect decreased with decreasing time of exposure to IC1 
164,384. The effect of IC1 164,384 on CATH-D mRNA levels 
corresponded to a parallel decrease in  EWSpl binding in  the 
EMSA (Fig. 5). 
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FIG. 4. Supershifting  of EWSpl  band with ER and Spl antibod- 
ies in EMSAs using MCF-7 cell nuclear  extracts. Cells  were  treated 
with 10 nhf E, (lanes 1-6) and  nuclear  extracts  were  incubated with 
radiolabeled  EWSpl oligo  followed  by incubation  with 20 ng of Sp l  Ab, 
100 ng of rabbit IgG, 100 ng of mouse IgG, 40 ng ER Ab, and  ER Ab 
(incubated for 18 h at 4 “C with ER peptide blocker; 40 ng). These 
nuclear  extracts  were  analyzed by electromobility  shift  assays as  de- 
scribed  under  “Materials  and Methods.” The  retarded  EWSpl  and su- 
per  shift (SS) bands  (see arrows) were  visualized by autoradiography. 
The  bands  in lanes 2 and 5 indicate  the  formation of a retarded  band  in 
addition  to  the  EWSpl  band  resulting from specific supershifting of the 
EWSpl  band by Spl  and ER Ab, respectively. 
CAT Assays-The results  in Fig. 8 summarize  the effects of 
10 nM E, on the induction of  CAT activity in MCF-7 cells tran- 
siently transfected with plasmids  containing the  EWSpl oligo 
and oligos with  mutations  in  the ERE (%RE’) or Spl  (‘Spl) 
genomic sequences. The  results  demonstrated  that E, induced 
a 5.9-fold increase  in CAT activity in cells transfected  with the 
plasmid  containing the  EWSpl oligo (lane 2 )  compared to cells 
treated  with Me,SO (control, lane 1 ) .  In  contrast, CAT activi- 
ties  in Me,SO and E,-treated cells transiently transfected with 
the plasmids  containing oligos mutated  in  the ERE (lunes 6 and 
7, respectively) or Sp l  (lanes 8 and 9, respectively)  sequence 
were not significantly different. Relatively high constitutive 
CAT activity was observed in  extracts from cells transiently 
transfected with the plasmid containing the mutated ERE 
(lanes 6 and 7). In MCF-7 cells transfected with  the estrogen- 
responsive EWSpl-thymidine kinase-CAT plasmid, IC1 
164,384 caused a concentration-dependent  decrease in E,-in- 
duced CAT activity (lanes 3 through 5). In separate experi- 
ments  (data not  shown),  incubation of MCF-7 cell nuclear ex- 
tracts with the  mutant oligos,  ‘ERE’ISpl and EREI’Spl, did not 
result  in formation of an  ER-Spl complex as determined by 
EMSAs. 
DISCUSSION 
CATH-D is an estrogen-regulated gene which requires a 
functional ER for transactivation. Previous studies  have dem- 
onstrated  that IC1 164,384, a “pure“  antiestrogen, which inhib- 
ERlSpl- 1 
Free  probe- -* 
1 2 3 4 5 6  
FIG. 5. Binding  of nuclear  extracts from MCF-7 cells treated 
with  1 p IC1 164,384 for 8,6,4, and 2 h (lunes 3-6, respectively). 
Nuclear  extracts from these cells were  isolated  and  analyzed by elec- 
tromobility  shift  assays as  described under  “Materials  and Methods.” 
The  retarded  EWSpl  bands  (see arrow) were visualized by autoradiog- 
raphy  and  quantitated  using  a  Betagen 603 Betascope blot analyzer. 
The  intensity  values  in lanes 2-6 relative  to the control band (lane 1, 
2-6, respectively; means 2 S.D. for three  determinations).  The  intensi- 
100 2 15%) were 230 2 28,lO 2 5,25 f 7,64 2 11, and 145 2 146 (lanes 
ties  in lanes 3 4  were  all  significantly lower ( p  < 0.05) than observed in 
E,-treated cells (lane 2 ). 
its formation of the nuclear ER homodimer (35) also inhibited 
E,-induced CATH-D  mRNA levels and secretion of this protein. 
The  results summarized in Fig. 4 illustrate  the time-dependent 
inhibition of E,-induced CATH-D mRNA levels and  this re- 
sembled the reported  parallel  decrease in ER homodimer lev- 
els. Analyses of the 5‘-promoter region of the CATH-D gene 
have identified  several Sp l  binding sites  in  the sense and an- 
tisense  strands  as well as GC boxes which are typical of “house- 
keeping“ genes (36). Redecker and co-workers (36) did not iden- 
tify a functional TATA box in  the 5-region, whereas estrogen 
induces TATA-dependent initiation of  CATH-D gene transcrip- 
tion  almost exclusively from transcription  start  site I (12). It 
was suggested that  the differences observed in  these  studies 
may be due to differential regulation of gene  transcription by 
estrogen (from transcription start site  I)  and calcitriol (possibly 
from transcription  start  site V) (12).  Examination of the non- 
coding strand of the CATH-D promoter shows that  it contains a 
GGGCG(n),,ACGGG (-1991-165) EWSpl sequence similar to 
that described for the E,-regulated myc protooncogene (29). 
This  study  demonstrates  that  the EFUSpl sequence plays a role 
in  the regulation of  CATH-D gene transcription by estrogens. 
The characteristic EMSA pattern  in Fig. 1 shows that EFU 
Spl  complexes are formed in vitro using nuclear  extracts from 
MCF-7 cells and a 32P-labeled EFUSpl oligonucleotide which 
corresponds to  the sequences identified on the CATH-D pro- 
moter. In addition,  preincubation  with  several unlabeled oligo- 
nucleotides (Fig. 1, lanes 3-12) confirms the specific involve- 
ment of the ER and  Spl proteins in  this complex. The result,s 
illustrated  in Figs. 2-4 further  support  our hypothesis that ER 
and  Spl proteins are directly involved in formation of the ER. 
Sp l  complex. EMSAs of nuclear  extracts from MCF-7 cells in- 
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FIG. 6. Binding  of  nuclear  extracts from HeLa cells treated 
with Me,SO (lane 3) and  nuclear  extracts from HeLa cells co- 
transfected  with hER and treated  with Me,SO (lane 1) and 10 n~ 
E, (lanes 2, 4, 5, and 6). The nuclear extracts were isolated and 
analyzed by electromobility shift  assays as described under “Materials 
and Methods.” The retarded  EWSpl and Spl  bands  (see arrows) were 
visualized by autoradiography  and quantitated using the Betagen 603 
Betascope blot analyzer. The  intensity  value for the EFUSpl banding 
E,-treated cells (lane 2 ) was 270 -c 20% relative to the control band (lune 
1,100 = 17%). No significant binding for the EFUSpl band  was observed 
from lanes 3 to 7. The  intensity  values for the  Spl band in lane 4 is 22 
2 3% when compared to Me,SO-treated HeLa cells in lune 3 (100 14%). 
The specific preincubation with an 100-fold excess of cold Sp l  oligo 
prevents any significant EWSpl  and Spl  binding. 
cubated with 32P-labeled oligos mutated  in  the  Spl  or ERE 
half-site did not form an  ER-Spl complex (Fig. 2, lanes 4 and 1, 
respectively). Immunodepletion of ER or Spl  from nuclear ex- 
tracts (Fig. 3, lanes 3 and 4 )  decreases formation of the  EWSpl 
complex in vitro; moreover, the  ER.Spl complex is supershifted 
after incubation with ER or Spl  antibodies (Fig. 4, lanes 5 and 
2, respectively). The  requirement for the ER in formation of the 
ER-Spl complex was confirmed by measuring EWSpl binding 
in nuclear  extracts from HeLa cells in  the presence or absence 
of cotransfected hER (Fig. 5) and  in MCF-7 cells treated with 
the antiestrogen IC1 164,384 (Fig. 5). EMSA analysis of ex- 
tracts from HeLa cells (Fig. 1) demonstrated that formation of 
the  ER*Spl complex was observed  only after transfection with 
hER in  the absence (lane 1 ) or presence (lane 2) of  E, and,  in 
MCF-7  cell nuclear extracts, the band intensity  was decreased 
by competition with excess unlabeled ERE, Spl,  and  EWSpl 
oligos. The  antiestrogen IC1 164,384 interferes  with formation 
of the ER  homodimer resulting  in decreased nuclear estrogen 
receptor levels (35). Treatment of  MCF-7 cells with IC1  164,384 
resulted in a time-dependent decrease in CATH-D  mRNA levels 
(Fig. 71, and  this corresponded with the reported time-depend- 
ent decrease in nuclear ER levels in these cells (35) and paral- 
CATH-D 
& 4- &Tubulin 
1 2 3  4 5  6 7 
Fro. 7. Northern analysis of  mRNA from MCF-7 cells treated 
with IC1  164,384. The cells were treated with Me,SO (lane 1 ), 10 n~ E, 
for 24 h (lane 2) and 1 p~ IC1 164,384 for 8 h (lane 3). Cells were 
cotreated  with  10 nM E, for 24 h and 1 p~ IC1  164,384 for 8,6,4,  and 2 
h (lanes 4-7, respectively). Cell extracts were obtained and total RNA 
was isolated and subjected to Northern analysis as described under 
“Materials and Methods.” The blots were visualized by autoradiography 
and quantitated using a Betagen 603 Betascope blot analyzer. The 
intensity  values in lanes 2-7 relative to the control lane (lane 1, 100 f 
6%) were 176 2 8,55 2 8,80 f 5,105 2 4,123 = 6, and  163 2 12% (lanes 
2-7, respectively; means -+ S.D. for three determinations).  The  intensi- 
ties  in lanes 3 through 5 were all significantly lower ( p  e 0.05) than 
observed in the E,-treated cells (lune 2); the intensity values for 
CATH-D were standardized to p-tubulin which was used as   an internal 
control. 
ERlSpl 
prod. 
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FIG. 8. Effect  of  IC1  164,384 on E,-induced  EWSpl-thymidine 
kinase-CAT activity  in MCF-7 cells. The cells were co-transfected 
with hER and EFUSpl-thymidine kinase-CAT (lanes 1-5) or ‘ERE’ISpl- 
thymidine kinase-CAT (mutated ERE half-site) (lanes 6 and 7) or EFU 
‘Spl-thymidine kinase-CAT (mutated Spl  site) (lanes 8 and 9) plas- 
mids. The transient transfection assay was performed as described 
under “Materials  and Methods.” Cells were treated with Me,SO (lane 
1 ), 10 nM E,  for 48  h (lane 2), 1 PM IC1  164,384  for  24 h (lane 3), E, + 1 
p~ IC1 164,384 (lane 4 ) ,  and E, + 0.1 PM IC1 164,384 (lane 8 ,  Me,SO 
(lane 6), 10 I” E, (lane 7), Me,SO (lane 8),  and 10 I” E, (lane 9). The 
relative  intensity  values for lanes 2-5 when compared to control cells 
(lane 1,100 2 20%) were 590 * 100,80 2 113,250 * 70, and 340 2 50% 
(lanes 2-5, respectively; means S.D. for three determinations). The 
relative  intensity  values for E,-treated cells (lane 7) when compared to 
control cells (lane 6, 100 f 11%) was 75 2 17%. The  relative  intensity 
values for E,-treated cells (lane 9 )  when compared to control cells (lane 
8,100 2 13%) was  98 * 20%. The  intensity values for lanes  through 5 are 
significantly lower ( p  < 0.05) than E,-treated cells (lane 2);  the  results 
expressed above for the two mutated plasmids (‘ERE’ and ‘Spl) are 
from  two separate experiments and  are expressed as means f S.D. for 
three determinations. 
leled the time-dependent decrease in  EWSpl binding in MCF-7 
cells (Fig. 5). These data demonstrate that the EWSpl se- 
quence located in  the promoter region of the CATH-D gene 
binds both ER and  Spl. 
The functional activity of the CATH-D EWSpl sequence was 
investigated by cloning the sequence upstream to a thymidine 
Estrogen-induced  Cathepsin D Gene Banscription 15917 
kinase promoter with a CAT reporter gene as previously de- 
scribed (25). The results (Fig. 8)  demonstrate that  the EFUSpl 
sequence is estrogen-responsive (lane 2 )  and IC1 164,384 in- 
hibits  the E,-induced response (lanes 3-5). The requirement of 
the ElUSpl sequence for estrogen-responsiveness was further 
investigated using plasmids which contain mutations  in the 
ERE-half site (‘ERE’) and in the Spl sequence ( ‘Spl ) .  The 
constitutive CAT activity in extracts from cells transiently 
transfected with these plasmids was highly variable (Fig. 8, 
lanes 6 and 8), and it was evident that a higher overall induc- 
tion response was observed  for the plasmid containing a mu- 
tated ERE-half site  but an intact Spl sequence. These data 
demonstrate that Spl-mediated transcriptional activation from 
the mutated ‘ERE’-promoter is not dependent on a functional 
ERE half-site whereas mutations  in the  Spl oligo resulted in 
only minimal induction of  CAT activity by  E,. However, despite 
the differences in  the constitutive CAT activities of extracts 
from cells transiently transfected with plasmids containing 
ERE.half site or Spl mutations, E, did not induce CAT activity 
in these assays. In addition, the  mutant oligos  did not form an 
ER.Sp1 complex as determined by  EMSAs (Fig. 2). Thus, these 
data confirm the requirement for an intact EFUSpl sequence  for 
estrogen-responsiveness. 
The molecular mechanism for Spl-mediated  transcriptional 
activation has not been unequivocally determined; however, 
there  is evidence that TATA binding factors including TFIID 
and  other coactivators may be required (27,371. Similar mecha- 
nisms may also govern EFUSpl-mediated transactivation in 
which coactivators may play a role.  However, at present, the 
nature of the specific  protein-DNA and protein-protein interac- 
tions required for the induction response have not been deter- 
mined and are currently being investigated in  this laboratory. 
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